CNS

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

Controlling for personality traits in clinical studies can deliver significant improvements in trial precision, with implications particularly relevant for CNS drug development

FDA approval of a new indication for Teva’s risperidone long-acting injectable Uzedy expands its reach beyond schizophrenia, unlocking a major growth opportunity in the bipolar I disorder market.

2026 is positioned as a breakout year for the psychedelic therapeutics sector, with multiple players expected to deliver defining Phase III results – creating momentum across the industry.

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.

A massive new proteomics dataset promises to accelerate target identification, biomarker discovery and precision medicine approaches in Alzheimer's, Parkinson's and other neurodegenerative diseases.

Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.

Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.

Harness Therapeutics' CEO talked to In Vivo about the company's strategy for expansion and partnering in the neurodegeneration space.

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company’s monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.